Treatment of minimal residual disease in myeloid malignancies after allo-HSCT with venetoclax-based regimens in patients ineligible for or failed in the immunotherapy

Background: Relapse was the major cause of treatment failure in patients with myeloid malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients who still suffer from the disease while cannot be detected by morphological analysis can be identified by the minimal resi...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Wen-Jing Yu, Jun Kong, Feng-Mei Zheng, Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yuan-Yuan Zhang, Yu-Qian Sun, Jian Jin, Xiao-Jun Huang, Yu Wang
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Taylor & Francis Group 2024-12-01
Seri Bilgileri:	Hematology
Konular:	Minimal residual disease venetoclax allogeneic hematopoietic stem cell transplantation myeloid malignancies
Online Erişim:	https://www.tandfonline.com/doi/10.1080/16078454.2024.2418653
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!